WHWK Key Statistics, Chart & Performance
The current stock price of WHWK is 2.81 USD. In the past month the price increased by 9.34%.
WHWK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to WHWK.
WHWK Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to WHWK. No worries on liquidiy or solvency for WHWK as it has an excellent financial health rating, but there are worries on the profitability.
WHWK Financial Highlights
Over the last trailing twelve months WHWK reported a non-GAAP Earnings per Share(EPS) of -2.06. The EPS increased by 9.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.35% | ||
| ROE | -9.94% | ||
| Debt/Equity | 0 |
WHWK Forecast & Estimates
10 analysts have analysed WHWK and the average price target is 4.59 USD. This implies a price increase of 63.35% is expected in the next year compared to the current price of 2.81.
For the next year, analysts expect an EPS growth of 88.14% and a revenue growth -72.66% for WHWK
WHWK Ownership
WHWK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.32 | 393.136B | ||
| AMGN | AMGEN INC | 16.18 | 196.357B | ||
| GILD | GILEAD SCIENCES INC | 16.51 | 182.665B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.73 | 117.594B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.25 | 79.341B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.21 | 42.669B | ||
| INSM | INSMED INC | N/A | 31.681B | ||
| NTRA | NATERA INC | N/A | 29.21B | ||
| BIIB | BIOGEN INC | 12.42 | 27.736B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.376B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About WHWK
Company Profile
Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 22 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Company Info
WHITEHAWK THERAPEUTICS INC
2 Headquarters Plaza, East Building, 11Th Floor
Morristown NEW JERSEY US
Employees: 22
Phone: 15513212234
WHITEHAWK THERAPEUTICS INC / WHWK FAQ
What does WHWK do?
Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 22 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
What is the stock price of WHITEHAWK THERAPEUTICS INC today?
The current stock price of WHWK is 2.81 USD. The price increased by 1.08% in the last trading session.
Does WHITEHAWK THERAPEUTICS INC pay dividends?
WHWK does not pay a dividend.
What is the ChartMill rating of WHITEHAWK THERAPEUTICS INC stock?
WHWK has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of WHITEHAWK THERAPEUTICS INC (WHWK) based on its PE ratio?
WHITEHAWK THERAPEUTICS INC (WHWK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.06).
What is WHITEHAWK THERAPEUTICS INC worth?
WHITEHAWK THERAPEUTICS INC (WHWK) has a market capitalization of 132.44M USD. This makes WHWK a Micro Cap stock.
Can you provide the upcoming earnings date for WHITEHAWK THERAPEUTICS INC?
WHITEHAWK THERAPEUTICS INC (WHWK) will report earnings on 2026-03-17, after the market close.